Two months to the day before its Dec. 24 PDUFA date, Xofluza (baloxavir marboxil, previously S-033188, RG-6152), gained a nod from the FDA to treat acute uncomplicated influenza in individuals 12 and older who became symptomatic within the previous 48 hours. Read More
HONG KONG – Singapore's Agency for Science, Technology and Research (A*STAR) has initiated the Pharma Innovation Programme Singapore (PIPS) aimed at bringing together the city-state's public sector research capabilities and major global players in the pharma industry to transform the manufacturing operations and technologies of the industry for greater efficiencies. Read More
HONG KONG – Leading Chinese vaccine maker Sinovac Biotech Ltd. resorted to the Hong Kong courts to fight off an attempted "coup" by a minority shareholder – an attempt that involved presenting allegedly fake documents filed in Hong Kong that suggested top management at Sinovac Biotech's holding company had resigned. Read More
Canbridge Pharmaceuticals Inc., of Beijing, and Wuxi Biologics Cayman Inc., of Shanghai, are partnering to develop and commercialize a portfolio of biotherapeutics for the treatment of rare diseases. Wuxi will contribute its discovery, development and manufacturing capabilities, while Canbridge will add its clinical, regulatory and commercial expertise. Read More
